Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

por Tyring, Stephen K., Rich, Phoebe, Tada, Yayoi, Beeck, Stefan, Messina, Izabella, Liu, Jie, Huang, Xiaohong, Shumack, Stephen
Publicado 2023

Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial

por Kimball, Alexa B., Prens, Errol P., Passeron, Thierry, Maverakis, Emanual, Turchin, Irina, Beeck, Stefan, Drogaris, Leonidas, Geng, Ziqian, Zhan, Tianyu, Messina, Izabella, Bechara, Falk G.
Publicado 2023

Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study

por Crowley, Jeffrey J., Langley, Richard G., Gordon, Kenneth B., Pinter, Andreas, Ferris, Laura K., Rubant, Simone, Photowala, Huzefa, Xue, Zhenyi, Wu, Tianshuang, Zhan, Tianyu, Beeck, Stefan, Shah, Megha, Warren, Richard B.
Publicado 2022